103882-84-4 Usage
Description
Gemcitabine, also known as 2',2'-difluorodeoxycytidine, is a synthetic nucleoside analog with potent anti-cancer properties. It is designed to mimic the structure of the nucleoside cytidine, which is a building block of DNA. Gemcitabine interferes with the process of DNA synthesis and repair, leading to the disruption of cancer cell replication and ultimately causing cell death. Its unique mechanism of action and effectiveness against various types of solid tumors make it a valuable pharmaceutical compound in the field of oncology.
Uses
Used in Anticancer Applications:
Gemcitabine is used as an anticancer agent for the treatment of solid tumors. It is particularly effective against a wide range of malignancies, including pancreatic, non-small cell lung, breast, ovarian, and bladder cancers. The drug works by inhibiting DNA synthesis, which prevents the cancer cells from dividing and proliferating, thereby slowing down tumor growth and progression.
Used in Combination Therapies:
Gemcitabine is often used in combination with other chemotherapeutic agents to enhance the overall effectiveness of cancer treatment. The synergistic action of gemcitabine with other drugs can help overcome drug resistance, increase chemo-sensitivity, and improve the therapeutic outcomes for patients with various types of solid tumors.
Used in Personalized Medicine:
Gemcitabine's effectiveness can be tailored to individual patients based on their specific genetic and molecular profiles. This personalized approach allows for the optimization of treatment regimens, minimizing side effects and maximizing the potential for successful cancer treatment.
Used in Drug Delivery Systems:
To improve the bioavailability, delivery, and therapeutic outcomes of gemcitabine, various drug delivery systems have been developed. These systems, which include liposomes, nanoparticles, and polymeric carriers, aim to enhance the drug's solubility, stability, and targeted delivery to cancer cells, thereby reducing systemic toxicity and improving patient compliance.
Check Digit Verification of cas no
The CAS Registry Mumber 103882-84-4 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,0,3,8,8 and 2 respectively; the second part has 2 digits, 8 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 103882-84:
(8*1)+(7*0)+(6*3)+(5*8)+(4*8)+(3*2)+(2*8)+(1*4)=124
124 % 10 = 4
So 103882-84-4 is a valid CAS Registry Number.
InChI:InChI=1/C9H11F2N3O4/c10-9(11)6(16)4(3-15)18-7(9)14-2-1-5(12)13-8(14)17/h1-2,4,6-7,15-16H,3H2,(H2,12,13,17)/t4-,6-,7-/m1/s1
103882-84-4Relevant articles and documents
Stereospecific synthesis of 2-deoxy-2,2-difluororibonolactone and its use in the preparation of 2'-deoxy-2',2'-difluoro-β-D-ribofuranosyl pyrimidine nucleosides: The key role of selective crystallization
Chou,Heath,Patterson,Poteet,Lakin,Hunt
, p. 565 - 570 (1992)
A stereospecific synthesis of 2'-deoxy-2',2'-difluorocytidine (gemcitabine), a potential anticancer agent, is described. The stereoselectivity was accomplished via two diastereoselective crystallizations, i.e. the crystallization of the key intermediate, difluororibonolactone 2a, and the crystallization of the hydrochloride salt of gemcitabine 16b from the anomeric mixture. Because of the availability of 2a in large quantities, other 2'-deoxy-2',2'-difluoropyrimidine nucleosides such as 2'-deoxy-2',2'-difluorouridine (19) were synthesized for structure-activity relationship studies.